Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotechnology pioneer advancing DARPin therapeutics for oncology and radiopharmaceutical applications. This page provides investors and industry observers with official company announcements, clinical trial milestones, and strategic partnership updates.
Access the latest developments in MOLN's Radio-DARPin Therapy platform, Switch-DARPin candidates, and ophthalmology programs. Our curated news collection enables efficient tracking of regulatory filings, preclinical data disclosures, and financial results without promotional commentary.
Key content categories include clinical trial progress, collaborative research updates with partners like Orano Med, and technology platform innovations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for centralized access to Molecular Partners' verified announcements. For comprehensive analysis of MOLN stock performance, visit Stock Titan's dedicated market data section.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced its interim management statement for Q3 2022, reporting significant progress in its oncology programs, including MP0317 and MP0533. The initial clinical data for MP0317 will be presented at SITC in November 2022, while MP0533 is on track for clinical development by year-end. Financial highlights include CHF 267 million in cash and an operating profit of CHF 132 million for the nine months ending September 30, 2022. The company expects to be funded into 2026, excluding R&D partnership revenues.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the departure of Chief Financial Officer, Andreas Emmenegger, at the end of 2022. Emmenegger, who has been with the company for 15 years, will aid in the transition while a replacement is sought. CEO Patrick Amstutz praised Emmenegger’s contributions, highlighting the successful IPOs on both the SIX Swiss Exchange and Nasdaq under his financial leadership. Molecular Partners focuses on DARPin therapeutics, with numerous partnerships and ongoing clinical developments across various therapeutic areas.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced key corporate highlights and financial results for H1 2022, reporting total revenues of CHF 184.5 million, attributed mainly to a CHF 150 million payment from Novartis for licensing ensovibep. The company holds a strong cash position of CHF 285.1 million expected to fund operations into 2026.
Ongoing clinical developments include MP0317 and MP0533, with initial data from MP0317 anticipated in H2 2022. Molecular Partners' strategic focus is on advancing novel DARPin therapeutics to address significant health challenges.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) will release its H1 2022 highlights and financial results on August 25, 2022, at 4:30 pm ET. Following this, an analyst and investor call is scheduled for August 26, 2022, at 8:00 am ET. The call will be webstreamed and available for 90 days post-event. Molecular Partners focuses on DARPin therapeutics, aiming to address challenges in diverse medical fields including ophthalmology, oncology, and infectious diseases.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced preclinical findings on ensovibep, a tri-specific DARPin therapeutic targeting SARS-CoV-2, published in Nature Biotechnology. Key results demonstrate ensovibep's ability to bind to all units of the viral spike protein, inhibiting ACE2 interaction. It shows efficacy against SARS-CoV-2 variants, including Omicron strains. These findings support ongoing clinical development for Emergency Use Authorization by the FDA. Molecular Partners plans to expand its antiviral DARPin portfolio for future health threats.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced its participation in several key conferences in June 2022, highlighting developments in their DARPin therapeutics aimed at treating various diseases. At the European Hematology Association Conference, they will present data on MP0533, a T-cell engager targeting tumors. Additionally, Novartis will showcase preclinical data on ensovibep, a COVID-19 treatment. Presentations also include discussions on ensuring safety and efficacy for AML therapies. Further details can be accessed via their official website.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 - Molecular Partners (SIX: MOLN; NASDAQ: MOLN) announced its interim management statement for Q1 2022, showcasing a strong cash position of CHF 296.2 million and revenue of CHF 172.8 million, largely from Novartis's exercise of its option for ensovibep. Positive Phase 2 results for ensovibep demonstrated a 78% reduction in hospitalization risks. The company is advancing its internal pipeline, including new candidates MP0310 and MP0533, and is expected to be funded into 2026.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm specializing in DARPin therapeutics, will participate in two investor events in May. The company is set to publish its Q1 2022 earnings report on May 12, 2022, after NASDAQ trading hours. Key events include the RBC Capital Markets Global Healthcare Conference from May 17-18, featuring a fireside chat on May 17 at 9:00 am ET, and BioEquity Europe 2022 with virtual meetings on May 23-24. Presentations will be available online.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that CEO Patrick Amstutz has been elected President of the Swiss Biotech Association. This leadership change signifies a commitment to fostering collaboration within the biotech sector, especially in response to global medical needs. Dr. Amstutz aims to support the growth of the Swiss biotech ecosystem, emphasizing the importance of innovation. He succeeds Dominik Escher, who held the position for 20 years. The announcement coincided with Dr. Amstutz's participation in a panel discussion on pandemic response strategies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the return of global rights for MP0310 from Amgen following a strategic review. MP0310, targeting FAP and 4-1BB, is currently in a Phase 1 trial, with full data expected later this year. Initial results show promise in activating immune responses in tumor microenvironments. This collaboration, started in December 2018, included a $50 million upfront payment, but no further clinical studies are planned until discussions with potential new partners post-trial completion.
FAQ
What is the current stock price of MOLECULAR PARTNERS (MOLN)?
What is the market cap of MOLECULAR PARTNERS (MOLN)?
